Elena Quaglino

Prof. Elena Quaglino

Department of Molecular Biotechnology and Health Sciences University of Torino, Italy
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in The Journal of Immunology
Verified
Journal Article
Open access
SRStefania Rovero
Stefania Rovero
AAAugusto Amici
Augusto Amici
ECEmma Di Carlo
Emma Di Carlo
RBRoberto Bei
Roberto Bei
PNPatrizia Nanni
Patrizia Nanni
GFGuido Forni
Guido Forni
The ability of vaccination with plasmids coding for the extracellular and the transmembrane domain of the product of transforming rat Her-2/neu oncogene (r-p185) to protect against r-p185+ transplantable carcinoma (TUBO) cells and mammary carcinogenesis was evaluated. In normal BALB/c mice, DNA vaccination elicits anti-r-p185 Ab, but only a marginal CTL reactivity, and protects against a TUBO cell challenge. Massive reactive infiltration is associated with TUBO cell rejection. In BALB/c mice transgenic for the rat Her-2/neu gene (BALB-neuT), DNA vaccination elicits a lower anti-r-p185 Ab response, no CTL activity and only incompletely protects against TUBO cells, but markedly hampers the progression of carcinogenesis. At 33 wk of age, when control BALB-neuT mice display palpable tumors in all mammary glands, about 60% of immunized mice are tumor free, and tumor multiplicity is markedly reduced. Tumor-free mammary glands still display the atypical hyperplasia of the early stages of carcinogenesis, and a marked down-modulation of r-p185, along with a massive reactive infiltrate. However, BALB-neuT mice protected against mammary carcinogenesis fail to efficiently reject a TUBO cell challenge. This suggests that the mechanisms required for the rejection of transplantable tumors may not coincide with those that inhibit the slow progression of carcinogenesis.

6 December 2010 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
Marta CosciaMarta Coscia
Marta Coscia
Elena QuaglinoElena Quaglino
Elena Quaglino
MIManuela Iezzi
Manuela Iezzi
CCClaudia Curcio
Claudia Curcio
FPFrancesca Pantaleoni
Francesca Pantaleoni
MMMassimo Massaia
Massimo Massaia
It is unknown whether zoledronic acid (ZA) at clinically relevant doses is active against tumours not located in bone. Mice transgenic for the activated ErbB‐2 oncogene were treated with a cumulative number of doses equivalent to that recommended in human beings. A significant increase in tumour‐free and overall survival was observed in mice treated with ZA. At clinically compatible concentrations, ZA modulated the mevalonate pathway and affected protein prenylation in both tumour cells and macrophages. A marked reduction in the number of tumour‐associated macrophages was paralleled by a significant decrease in tumour vascularization. The local production of vascular endothelial growth factor and interleukin‐10 was drastically down‐regulated in favour of interferon‐γ production. Peritoneal macrophages and tumour‐associated macrophages of ZA‐treated mice recovered a full M1 antitumoral phenotype, as shown by nuclear translocation of nuclear factor kB, inducible nitric oxide synthase expression and nitric oxide production. These data indicate that clinically achievable doses of ZA inhibit spontaneous mammary cancerogenesis by targeting the local microenvironment, as shown by a decreased tumour vascularization, a reduced number of tumour‐associated macrophages and their reverted polarization from M2 to M1 phenotype.

5 April 2011 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
EPElisa Penna
Elisa Penna
FOFrancesca Orso
Francesca Orso
DCDaniela Cimino
Daniela Cimino
ETEnrico Tenaglia
Enrico Tenaglia
ALAntonio Lembo
Antonio Lembo
Daniela TavernaDaniela Taverna
Daniela Taverna
Malignant melanoma is fatal in its metastatic stage. It is therefore essential to unravel the molecular mechanisms that govern disease progression to metastasis. MicroRNAs (miRs) are endogenous non‐coding RNAs involved in tumourigenesis. Using a melanoma progression model, we identified a novel pathway controlled by miR‐214 that coordinates metastatic capability. Pathway components include TFAP2C, homologue of a well‐established melanoma tumour suppressor, the adhesion receptor ITGA3 and multiple surface molecules. Modulation of miR‐214 influences in vitro tumour cell movement and survival to anoikis as well as extravasation from blood vessels and lung metastasis formation in vivo. Considering that miR‐214 is known to be highly expressed in human melanomas, our data suggest a critical role for this miRNA in disease progression and the establishment of distant metastases. There is a [Have you seen?][1] (May 2011) associated with this Article. [1]: http://dx.doi.org/10.1038/emboj.2011.132

14 March 2010 in Cancer Research
Verified
Journal Article
Closed access
IBIsaia Barbieri
Isaia Barbieri
SPSara Pensa
Sara Pensa
TPTania Pannellini
Tania Pannellini
Elena QuaglinoElena Quaglino
Elena Quaglino
DMDiego Maritano
Diego Maritano
VPValeria Poli
Valeria Poli
The transcription factor signal transducer and activator of transcription 3 (STAT3) is constitutively activated in tumors of different origin, but the molecular bases for STAT3 requirement are only partly understood. To evaluate the contribution of enhanced Stat3 activation in a controlled model system, we generated knock-in mice wherein a mutant constitutively active Stat3C allele replaces the endogenous wild-type allele. Stat3C could enhance the tumorigenic power of the rat Neu oncogene in mouse mammary tumor virus (MMTV)–Neu transgenic mice, triggering the production of earlier onset, more invasive mammary tumors. Tumor-derived cell lines displayed higher migration, invasion, and metastatic ability and showed disrupted distribution of cell-cell junction markers mediated by Stat3-dependent overexpression of the COOH terminal tensin-like (Cten) focal adhesion protein, which was also significantly upregulated in Stat3C mammary tumors. Importantly, the proinflammatory cytokine interleukin-6 could mediate Cten induction in MCF10 cells in an exquisitely Stat3-dependent way, showing that Cten upregulation is a feature of inflammation-activated Stat3. In light of the emerging pivotal role of Stat3 in connecting inflammation and cancer, our identification of Cten as a Stat3-dependent mediator of migration provides important new insights into the oncogenic role of Stat3, particularly in the breast. Cancer Res; 70(6); 2558–67

11 December 2012 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
DCDaniela Cimino
Daniela Cimino
Cristiano De PittaCristiano De Pitta
Cristiano De Pitta
FOFrancesca Orso
Francesca Orso
MZMatteo Zampini
Matteo Zampini
SCSilvia Casara
Silvia Casara
Daniela TavernaDaniela Taverna
Daniela Taverna

15 April 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Elena QuaglinoElena Quaglino
Elena Quaglino
MIManuela Iezzi
Manuela Iezzi
CMCristina Mastini
Cristina Mastini
AAAugusto Amici
Augusto Amici
FPFederica Pericle
Federica Pericle
FCFederica Cavallo
Federica Cavallo
The transforming rat Her-2/neu oncogene embedded into the genome of virgin transgenic BALB/c mice (BALB-neuT) provokes the development of an invasive carcinoma in each of their 10 mammary glands. i.m. vaccination with DNA plasmids coding for the extracellular and transmembrane domains of the protein product of the Her-2/neu oncogene started when mice already display multifocal in situ carcinomas temporarily halts neoplastic progression, but all mice develop a tumor by week 43. By contrast, progressive clearance of neoplastic lesions and complete protection of all 1-year-old mice are achieved when the same plasmids are electroporated at 10-week intervals. Pathological findings, in vitro tests, and the results from the immunization of both IFN-γ and immunoglobulin gene knockout BALB-neuT mice, and of adoptive transfer experiments, all suggest that tumor clearance rests on the combination of antibodies and IFN-γ-releasing T cells. These findings show that an appropriate vaccine effectively inhibits the progression of multifocal preneoplastic lesions.